TL;DR
Sutter Health opened a biobank registry in May 2026 to collect biological samples and clinical data from patients who meet clinical criteria for suspected LATE. At the time researchers submitted an abstract for a November conference, they had identified 21 eligible patients and enrolled six; the registry is intended to support biomarker research and potential future trials.
Sutter Health has opened a biobank registry to collect biological samples and clinical data from patients who meet clinical criteria for suspected LATE, a form of dementia that can resemble Alzheimer’s disease but is associated with a different brain protein. Researchers say the registry could help identify biomarkers and support future studies, though it is still in an early enrollment stage.
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
The LATE Biobank Registry gathers information from patients receiving care across Sutter’s California health system. Researchers plan to collect samples over time, including blood and cerebrospinal fluid, alongside clinical information. The aim is to study the disease, develop and validate possible biomarkers, and build a resource that could help prepare for future clinical trials.
Sutter’s researchers reported that the registry opened in May 2026. At the time they submitted an abstract for the Clinical Trials on Alzheimer’s Disease conference, they had identified 21 patients who met eligibility criteria; six had consented to participate. Dr. Shawn Kile, chair of Sutter Health’s Advanced Neuroscience Service Line, was scheduled to present early findings on the registry’s creation and initial enrollment in Boston on November 18.
LATE stands for limbic-predominant age-related TDP-43 encephalopathy. It is associated with abnormal accumulation of TDP-43 in brain regions involved in memory. Unlike Alzheimer’s disease, LATE currently has no specific biomarkers or known treatments, according to the source report. The registry’s stated purpose is research, not to provide a diagnostic test or treatment for participants.
Building a Research Cohort for LATE
The registry addresses a problem in dementia research: memory loss that resembles Alzheimer’s may have another underlying cause, and patients can have more than one brain pathology. Researchers say collecting samples and clinical histories together could help clarify which biological changes are associated with LATE and how they relate to symptoms.
For patients and families, a better way to distinguish LATE from Alzheimer’s could eventually improve the accuracy of research and clinical classification. Sutter says the registry may also provide a group of participants for future trials of treatments targeting TDP-43. Those are potential future uses; the available information does not show that the registry has produced a biomarker, treatment, or clinical benefit.
Products Worth Considering

Garmin Forerunner 165 GPS Running Smartwatch, 43 mm, Black

BowFlex Results Series SelectTech Adjustable Dumbbells (Pair)

Oura Ring 5 Smart Ring, Silver, Size 8
As an affiliate, we earn on qualifying purchases.
How LATE Differs From Alzheimer’s
LATE can look clinically similar to Alzheimer’s, but the conditions are linked to different proteins: LATE to TDP-43, and Alzheimer’s to amyloid and tau changes. The source report says researchers are identifying patients with memory problems who test negative for Alzheimer’s amyloid and tau biomarkers; some may have LATE, though a negative result alone does not establish that diagnosis.
The Alzheimer’s Association released clinical criteria for LATE in 2025. Sutter’s registry builds on that framework by connecting patients identified in routine care with samples and clinical records. Kile cited autopsy studies suggesting LATE pathology appears in about 40% of people aged 80 and older. That figure refers to findings in autopsy studies, not the proportion of older adults diagnosed through Sutter’s registry.
“Based on autopsy studies, we are learning that LATE pathology is showing up in approximately 40% of people age 80 and older.”
— Dr. Shawn Kile, chair of Sutter Health’s Advanced Neuroscience Service Line
Enrollment and Evidence Still Early
The reported enrollment numbers are an early snapshot: researchers had identified 21 eligible patients and obtained consent from six by the time of abstract submission. The source does not give an updated enrollment total, the registry’s target size, or details on how many participants will provide each type of sample.
It is also unclear when the registry could yield validated biomarkers or whether any future trial will launch. The source describes research aims, not results showing that the registry can diagnose LATE, distinguish it reliably from Alzheimer’s, or improve treatment. LATE pathology may be a primary contributor to cognitive decline in some people and may coexist with other pathology in others, Kile said.
Conference Findings and Further Enrollment
Kile was scheduled to present the registry’s establishment and initial enrollment at the Clinical Trials on Alzheimer’s Disease conference in Boston on November 18, 2026. The source material does not include results from that presentation, so any findings beyond the initial enrollment figures remain unreported here.
Sutter says eligible patients can enroll through participating affiliates across California. As enrollment continues, researchers plan to collect samples and clinical data over time, study candidate biomarkers, and build a cohort that may be useful for future trials targeting TDP-43. The timing and design of such trials have not been announced.
Key Questions
What is the Sutter LATE Biobank Registry?
It is a research registry collecting biological samples and clinical information from patients who meet clinical criteria for suspected LATE. Sutter says the material will be used to study the condition and potential biomarkers.
How is LATE different from Alzheimer’s disease?
LATE is associated with abnormal buildup of the TDP-43 protein in brain regions involved in memory. Alzheimer’s disease is associated with amyloid and tau changes. The conditions can produce similar symptoms, and the source says some patients may have more than one pathology.
How many people had joined the registry?
At the time researchers submitted their conference abstract, they had identified 21 eligible patients, and six had consented to participate. The source does not provide a later enrollment count.
Does the registry offer a LATE test or treatment?
No. The registry is a research project, and the source says LATE has no specific biomarkers or known treatments. Researchers hope the work may support future biomarker development and trials, but those outcomes have not been established.
Source: news-medical.net
